Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13030425 http://scihub22266oqcxt.onion/10.3390/v13030425 33800932!7999995!33800932     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (3): ä Nephropedia Template TP {{tp|p=33800932|t=2021. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2 |pdf=|usr=}}{{33800932}} gab.com Text The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2 JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33800932 #FOAvip Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is the cause of a worldwide pandemic, currently with limited therapeutic options. The spike glycoprotein and envelope protein of SARS-CoV-2, containing disulfide bridges for stabilization, represent an attractive target as they are essential for binding to the ACE2 receptor in host cells present in the nasal mucosa. Bromelain and Acetylcysteine (BromAc) has synergistic action against glycoproteins by breakage of glycosidic linkages and disulfide bonds. We sought to determine the effect of BromAc on the spike and envelope proteins and its potential to reduce infectivity in host cells. Recombinant spike and envelope SARS-CoV-2 proteins were disrupted by BromAc. Spike and envelope protein disulfide bonds were reduced by Acetylcysteine. In in vitro whole virus culture of both wild-type and spike mutants, SARS-CoV-2 demonstrated a concentration-dependent inactivation from BromAc treatment but not from single agents. Clinical testing through nasal administration in patients with early SARS-CoV-2 infection is imminent. Twit Text FOAVip The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2 ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33800932 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33800932 #FOAvip English Wikipedia <ref>{{Cite pmid|33800932}}</ref> The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2 #MMPMID33800932 Akhter J; Queromes G; Pillai K; Kepenekian V; Badar S; Mekkawy AH; Frobert E; Valle SJ; Morris DL Viruses 2021[Mar]; 13 (3): ä PMID33800932show ga Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is the cause of a worldwide pandemic, currently with limited therapeutic options. The spike glycoprotein and envelope protein of SARS-CoV-2, containing disulfide bridges for stabilization, represent an attractive target as they are essential for binding to the ACE2 receptor in host cells present in the nasal mucosa. Bromelain and Acetylcysteine (BromAc) has synergistic action against glycoproteins by breakage of glycosidic linkages and disulfide bonds. We sought to determine the effect of BromAc on the spike and envelope proteins and its potential to reduce infectivity in host cells. Recombinant spike and envelope SARS-CoV-2 proteins were disrupted by BromAc. Spike and envelope protein disulfide bonds were reduced by Acetylcysteine. In in vitro whole virus culture of both wild-type and spike mutants, SARS-CoV-2 demonstrated a concentration-dependent inactivation from BromAc treatment but not from single agents. Clinical testing through nasal administration in patients with early SARS-CoV-2 infection is imminent. |Acetylcysteine/*pharmacology[MESH] |Antiviral Agents/*pharmacology[MESH] |Bromelains/*pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*virology[MESH] |Drug Evaluation, Preclinical[MESH] |Drug Synergism[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects/genetics/growth & development/metabolism[MESH] |Spike Glycoprotein, Coronavirus/genetics/metabolism[MESH]The Combination of Bromelain and Acetylcysteine (BromAc) Synergistical(epmc).pdf DeepDyve Pubget Overpricing